The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with placebo1 Patients receiving...
Hence then, the article about new data from phase iii trial confirms efficacy of vyepti eptinezumab in asian population with chronic migraine was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine )
Also on site :
- Trump says Pam Bondi, a loyalist who oversaw Justice Department upheaval, is out as attorney general
- Ford and Toyota issue major South African car recall
- Target's 'Fabulous' Rattan Sideboard Cabinet Is Nearly 70% Off, and It's So 'Easy to Assemble'